ReviewHuman vaccines & immunotherapeutics2016
Nosocomial rotavirus infection: An up to date evaluation of European studies.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Clinical Outcomes and Characteristics of COVID-19 in Neonates: A Single-Center Study in Romania.Life (Basel, Switzerland) · 2024Article
- Article
- Inanimate Surfaces as a Source of Hospital Infections Caused by Fungi, Bacteria and Viruses with Particular Emphasis on SARS-CoV-2.International journal of environmental research and public health · 2022Review
- Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013-2018.BMC infectious diseases · 2021Observational
- Nosocomial infection caused by a rare G8P[8] rotavirus subtype in a pediatric unit in Guangzhou, Southern China.Human vaccines & immunotherapeutics · 2021Article
- Opinions and attitudes of Italian healthcare workers towards recommended but not compulsory rotavirus vaccination.Human vaccines & immunotherapeutics · 2021Article
- Universal rotavirus vaccination program in Sicily: Reduction in health burden and cost despite low vaccination coverage.Human vaccines & immunotherapeutics · 2018Observational
- Parents' insights after pediatric hospitalization due to rotavirus gastroenteritis in Italy.Human vaccines & immunotherapeutics · 2017Article
- Re-evaluation of the cost-effectiveness and effects of childhood rotavirus vaccination in Norway.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus (RV) is worldwide considered as the most important viral agent of acute gastroenteritis in children less than 5 y. Since 2006, the availability of anti-RV vaccines has deeply modified the incidence and economic burden of RV infection. In Europe, some countries have introduced an anti-RV vaccination program in the last 10 y. Although community acquired RV (CARV) disease is the most studied condition of RV infection, recently some authors have highlighted the importance of nosocomial RV (nRV) disease as an emerging public health issue. The aim of this review is to summarize the epidemiology of both CARV and nRV, in order to discuss the difficulty of a clear evaluation of the burden of the disease in absence of comparable data. In particular, we focused our attention to European studies regarding nRV in terms of divergences related to definition, report of incidence rate and methodological issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.